August 3, 2023 – A recent lawsuit filed by a girl with type 2 diabetes alleges that the makers of the drugs Ozempic and Mounjaro did not adequately warn concerning the severity of stomach problems attributable to the common medications.
The two drugs, approved by the FDA to treat type 2 diabetes, are known for his or her weight-reducing properties. Ozempic is made by Danish pharmaceutical company Novo Nordisk, and Mounjaro is made by Indiana-based Eli Lilly and Co.
In the lawsuit, Jaclyn Bjorklund, 44, of Louisiana, claims she was “seriously injured” after taking Ozempic and Mounjaro and that drug firms did not disclose the chance that the drugs cause vomiting and diarrhea on account of inflammation of the stomach lining, in addition to the chance of gastric paralysis. (The medical term for gastric paralysis is gastroparesis.)
The prescription labels for Mounjaro And Ozempic state that each “delay gastric emptying” and warn of the chance of significant gastrointestinal unwanted side effects. The package inserts for each drugs state that probably the most common unwanted side effects are vomiting, diarrhea, and stomach pain. The Ozempic package insert doesn't mention gastroparesis, and the Mounjaro package insert states that the drug has not been studied in individuals with the condition and is due to this fact not beneficial for victims.
Bjorklund has not been diagnosed with gastroparesis, but her symptoms are “indicative” of the condition, said her attorney Paul Pennock. NBC News.
Bjorklund used Ozempic for greater than a 12 months and moved to Mounjaro, the suit States. The document, posted on her law firm's website, describes that taking the drugs resulted in “severe vomiting, stomach pain, gastrointestinal burning, multiple hospitalizations for stomach problems, including visits to the emergency room, [and] Due to excessive vomiting, her teeth fell out, requiring additional medication to relieve excessive vomiting and vomiting entire food hours after eating.”
Novo Nordisk spokeswoman Natalia Salomao told NBC News that patient safety is “of paramount importance to Novo Nordisk,” and he or she also identified that gastroparesis is a known risk for diabetics. The FDA declined to comment on the case, and Eli Lilly didn't immediately reply to a request for comment, NBC News reported.